Men's Health News

RSS

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

7 Oct 2015

Recipients of 2015 Ferring Innovation Grants announced

Ferring Research Institute Inc. today announced the recipients of the 2015 Ferring Innovation Grants. This global program awards each recipient $50,000 to support research in the fields of Reproductive Health, Gastroenterology and/or Urology.

7 Oct 2015

Researchers study effect of immune tolerance on certain cancer risks

For a malignant tumor to form, cancer cells must evade the immune system's attack. Numerous studies have already shown that cancer spreads particularly aggressively if there is an unfavorable balance between suppressing and active immune cells in the tumor microenvironment. "But we didn't know whether this is a consequence of an aggressive tumor or rather its cause," says Rudolf Kaaks, epidemiologist at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).

7 Oct 2015

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with recurrent or metastatic castration resistant prostate cancer (IND 209). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.

6 Oct 2015

First-time expectant dads experience depression

Transition to parenthood can be a difficult life event. It can have an impact on both parents and on the long-term development of the child. While mother's "baby blues" have been widely investigated, little research has been conducted on antenatal paternal depression. A team from the Research Institute of the McGill University Health Centre sheds light on fathers' mental health by releasing the first study to report the prevalence of antenatal depression symptoms among Canadian men.

6 Oct 2015

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

A new population-based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five-year period was not associated with an increased risk of aggressive prostate cancer. Further, risk of high-grade prostate cancer did not increase according to the total number of testosterone injections.

5 Oct 2015

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years, leading to recurrence and, ultimately, death. A University of Houston researcher and his team are working to change that.

30 Sep 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Age, race and family history are the biggest risk factors for prostate cancer, new research suggests

New research suggests that age, race and family history are the biggest risk factors for a man to develop prostate cancer, although high blood pressure, high cholesterol, vitamin D deficiency, inflammation of prostate, and vasectomy also add to the risk. In contrast, obesity, alcohol abuse, and smoking show a negative association with the disease.

30 Sep 2015

New global educational initiative helps men identify symptoms of advanced prostate cancer

Although prostate cancer may exhibit no symptoms in its early stages, symptoms like severe or unexplained pain, difficulty walking or climbing stairs, difficulty sleeping or loss of bladder control may emerge when the disease advances as a signal to men to take action with their doctors.

29 Sep 2015

New global educational initiative helps men identify symptoms of advanced prostate cancer

29 Sep 2015

Fewer, higher doses of radiotherapy effective at treating prostate cancer

Giving fewer but higher doses of radiotherapy, is as effective at treating prostate cancer as giving lower doses for a longer period, according to new research* presented at the 2015 European Cancer Congress today (Monday).

28 Sep 2015

Fidgeting while sitting may be good for us

Fidgeting may counteract the adverse health effects of sitting down for long periods, according to a new study published in the American Journal of Preventive Medicine.

24 Sep 2015

Men with higher exposure to phthalate have lower sperm motility

Men with higher exposure to the substance DEHP, a so-called phthalate, have lower sperm motility and may therefore experience more difficulties conceiving children, according to a Lund University study.

24 Sep 2015

Discovery opens door to more targeted, effective treatments for cancer

In a discovery that could lead to more targeted and effective treatments for certain lung and prostate cancers, researchers at the University of Virginia School of Medicine have identified two new cancer-causing gene mutations - mutations that may be particularly susceptible to cancer-fighting drugs already approved by the federal Food and Drug Administration. One of the gene mutations also may play a key role in early menopause.

24 Sep 2015

Study uses genome- and epigenome-editing tools to determine disease-causing variants

A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.

24 Sep 2015

Family history: The most vital risk factor for prostate cancer

Family history is the most critical risk factor for prostate cancer. Men are more at risk if they had a father or brother with prostate cancer.

22 Sep 2015

USPSTF recommendation against regular PSA screening may delay diagnosis of prostate cancer

The U.S. Preventive Services Task Force recommendation against regular prostate specific antigen (PSA) screening for prostate cancer is controversial. While it may reduce the risk of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern because of the potential for delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators reporting in The Journal of Urology.

22 Sep 2015

New report calls for greater focus to address quality of life issues in prostate cancer patients

A new report released today entitled Prostate Cancer: Living, not Just Surviving, which details the findings from a large pan-European survey of 765 prostate cancer patients, 335 caregivers and 400 healthcare professionals, reveals that only 14 per cent of healthcare professionals feel that they have sufficient resources to address quality of life issues, such as fatigue, pain and intimacy problems.

18 Sep 2015

Coloplast announces launch of most compact catheter for men in the U.S.

Coloplast announced the U.S. launch of SpeediCath Compact Male, the most compact catheter for men, designed so users can do more. The new product is less than half the size of a standard male catheter and may be stored, carried, used and disposed of more discreetly.

15 Sep 2015

Men's Health News

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Recipients of 2015 Ferring Innovation Grants announced

Researchers study effect of immune tolerance on certain cancer risks

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

First-time expectant dads experience depression

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Age, race and family history are the biggest risk factors for prostate cancer, new research suggests

New global educational initiative helps men identify symptoms of advanced prostate cancer

New global educational initiative helps men identify symptoms of advanced prostate cancer

Fewer, higher doses of radiotherapy effective at treating prostate cancer

Fidgeting while sitting may be good for us

Men with higher exposure to phthalate have lower sperm motility

Discovery opens door to more targeted, effective treatments for cancer

Study uses genome- and epigenome-editing tools to determine disease-causing variants

Family history: The most vital risk factor for prostate cancer

USPSTF recommendation against regular PSA screening may delay diagnosis of prostate cancer

New report calls for greater focus to address quality of life issues in prostate cancer patients

Coloplast announces launch of most compact catheter for men in the U.S.

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News